Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.

Gutjahr A, Heck F, Emtenani S, Hammers AK, Hundt JE, Muck P, Siegel DL, Schmidt E, Stanley JR, Zillikens D, Hammers CM.

Br J Dermatol. 2019 Sep;181(3):593-594. doi: 10.1111/bjd.18156. Epub 2019 Jun 5. No abstract available.

PMID:
31124130
2.

Stephen I. Katz MD PhD 1941-2019.

Stanley JR, Hall RP 3rd.

Br J Dermatol. 2019 May;180(5):1268-1269. doi: 10.1111/bjd.17787. No abstract available.

PMID:
31025754
3.

Stephen I. Katz, MD, PhD, Professional and Personal Remembrances: In Memoriam.

Stanley JR.

JAMA Dermatol. 2019 Apr 1;155(4):417-419. doi: 10.1001/jamadermatol.2019.0214. No abstract available.

PMID:
30969337
4.

An Overview on the Considerations for the Planning of Nonclinical Necropsies for Medical Device Studies.

Stanley JRL, Keating JH, San Souci KJ.

Toxicol Pathol. 2019 Apr;47(3):213-220. doi: 10.1177/0192623319825821. Epub 2019 Feb 6. Review.

PMID:
30727861
5.

Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.

Emtenani S, Yuan H, Lin C, Pan M, Hundt JE, Schmidt E, Komorowski L, Stanley JR, Hammers CM.

Br J Dermatol. 2019 May;180(5):1099-1106. doi: 10.1111/bjd.17313. Epub 2019 Jan 1.

PMID:
30315657
6.

Research Techniques Made Simple: Mass Spectrometry for Analysis of Proteins in Dermatological Research.

Hammers CM, Tang HY, Chen J, Emtenani S, Zheng Q, Stanley JR.

J Invest Dermatol. 2018 Jun;138(6):1236-1242. doi: 10.1016/j.jid.2018.01.001. Review.

7.

Biocompatibility, bone healing, and safety evaluation in rabbits with an IlluminOss bone stabilization system.

McSweeney AL, Zani BG, Baird R, Stanley JRL, Hayward A, Markham PM, Kopia GA, Edelman ER, Rabiner R.

J Orthop Res. 2017 Oct;35(10):2181-2190. doi: 10.1002/jor.23532. Epub 2017 Feb 20.

8.

Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics.

Chen J, Zheng Q, Hammers CM, Ellebrecht CT, Mukherjee EM, Tang HY, Lin C, Yuan H, Pan M, Langenhan J, Komorowski L, Siegel DL, Payne AS, Stanley JR.

Cell Rep. 2017 Jan 3;18(1):237-247. doi: 10.1016/j.celrep.2016.12.013.

9.

Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering.

Yoshida K, Ishii K, Shimizu A, Yokouchi M, Amagai M, Shiraishi K, Shirakata Y, Stanley JR, Ishiko A.

J Dermatol Sci. 2017 Mar;85(3):197-207. doi: 10.1016/j.jdermsci.2016.12.010. Epub 2016 Dec 12.

10.

Ultra-hydrophilic stent platforms promote early vascular healing and minimise late tissue response: a potential alternative to second-generation drug-eluting stents.

Kolandaivelu K, Bailey L, Buzzi S, Zucker A, Milleret V, Ziogas A, Ehrbar M, Khattab AA, Stanley JRL, Wong GK, Zani B, Markham PM, Tzafriri AR, Bhatt DL, Edelman ER.

EuroIntervention. 2017 Apr 20;12(17):2148-2156. doi: 10.4244/EIJ-D-15-00497.

11.

Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Hammers CM, Stanley JR.

Annu Rev Pathol. 2016 May 23;11:175-97. doi: 10.1146/annurev-pathol-012615-044313. Epub 2016 Feb 22. Review.

12.

Patients with pemphigus foliaceus may retain antibody reactivity against calcium-stabilized, distal desmoglein 1 domains in remission.

Hammers CM, Stanley JR.

Br J Dermatol. 2016 Jan;174(1):17-8. doi: 10.1111/bjd.14262. No abstract available.

PMID:
26790650
13.

Tuning of collagen scaffold properties modulates embedded endothelial cell regulatory phenotype in repair of vascular injuries in vivo.

Unterman S, Freiman A, Beckerman M, Abraham E, Stanley JR, Levy E, Artzi N, Edelman E.

Adv Healthc Mater. 2015 Oct 28;4(15):2220-8. doi: 10.1002/adhm.201500457. Epub 2015 Sep 1.

14.

Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension.

Tzafriri AR, Keating JH, Markham PM, Spognardi AM, Stanley JR, Wong G, Zani BG, Highsmith D, O'Fallon P, Fuimaono K, Mahfoud F, Edelman ER.

Sci Transl Med. 2015 Apr 29;7(285):285ra65. doi: 10.1126/scitranslmed.aaa3236.

15.

Osteopetrorickets due to Snx10 deficiency in mice results from both failed osteoclast activity and loss of gastric acid-dependent calcium absorption.

Ye L, Morse LR, Zhang L, Sasaki H, Mills JC, Odgren PR, Sibbel G, Stanley JR, Wong G, Zamarioli A, Battaglino RA.

PLoS Genet. 2015 Mar 26;11(3):e1005057. doi: 10.1371/journal.pgen.1005057. eCollection 2015 Mar.

16.

Evaluation of an intramedullary bone stabilization system using a light-curable monomer in sheep.

Zani BG, Baird R, Stanley JR, Markham PM, Wilke M, Zeiter S, Beck A, Nehrbass D, Kopia GA, Edelman ER, Rabiner R.

J Biomed Mater Res B Appl Biomater. 2016 Feb;104(2):291-9. doi: 10.1002/jbm.b.33380. Epub 2015 Mar 12.

17.

Particulates from hydrophilic-coated guiding sheaths embolise to the brain.

Stanley JR, Tzafriri AR, Regan K, LaRochelle A, Wong G, Zani BG, Markham PM, Bailey L, Spognardi A, Kopia GA, Edelman ER.

EuroIntervention. 2016 Mar;11(12):1435-41. doi: 10.4244/EIJY15M03_02.

18.

Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation.

Sakakura K, Ladich E, Edelman ER, Markham P, Stanley JR, Keating J, Kolodgie FD, Virmani R, Joner M.

JACC Cardiovasc Interv. 2014 Oct;7(10):1184-93. doi: 10.1016/j.jcin.2014.04.024. Epub 2014 Sep 17. Review.

19.

Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.

Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR.

J Invest Dermatol. 2015 Mar;135(3):742-749. doi: 10.1038/jid.2014.291. Epub 2014 Jul 14.

20.

From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases.

Ludwig RJ, Borradori L, Diaz LA, Hashimoto T, Hertl M, Ibrahim SM, Jonkman MF, Kitajima Y, Murrell DF, Schmidt E, Shimizu H, Stanley JR, Woodley DT, Zillikens D.

J Invest Dermatol. 2014 Sep;134(9):2298-2300. doi: 10.1038/jid.2014.171. No abstract available.

21.

Evaluation of renal nerve morphological changes and norepinephrine levels following treatment with novel bipolar radiofrequency delivery systems in a porcine model.

Cohen-Mazor M, Mathur P, Stanley JR, Mendelsohn FO, Lee H, Baird R, Zani BG, Markham PM, Rocha-Singh K.

J Hypertens. 2014 Aug;32(8):1678-91; discussion 1691-2. doi: 10.1097/HJH.0000000000000236.

22.

Antibody phage display: technique and applications.

Hammers CM, Stanley JR.

J Invest Dermatol. 2014 Feb;134(2):1-5. doi: 10.1038/jid.2013.521. Review. No abstract available.

23.

Preclinical evaluation of the InCraft" aortic endograft in a sheep model.

Teigen C, Stanley JR, Johnsont P, Gross C.

Vascular. 2014 Feb;22(1):13-9.

PMID:
23592807
24.

Desmoglein-1, differentiation, and disease.

Hammers CM, Stanley JR.

J Clin Invest. 2013 Apr;123(4):1419-22. doi: 10.1172/JCI69071. Epub 2013 Mar 25.

25.

Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus.

Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, Makni S, Turki H, Hachiya T, Kuroda K, Stanley JR, Masmoudi H, Amagai M.

J Dermatol Sci. 2013 Apr;70(1):19-25. doi: 10.1016/j.jdermsci.2013.02.002. Epub 2013 Feb 19.

26.

Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb.

Kouno M, Lin C, Schechter NM, Siegel D, Yang X, Seykora JT, Stanley JR.

J Invest Dermatol. 2013 Sep;133(9):2212-20. doi: 10.1038/jid.2013.85. Epub 2013 Feb 25.

27.

Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study.

Attizzani GF, Bezerra HG, Chamié D, Fujino Y, Spognardi AM, Stanley JR, Yamamoto H, Mehanna E, Wang W, Carlyle WC, McClain JB, Costa MA.

J Invasive Cardiol. 2012 Nov;24(11):560-8.

28.

Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen PA, Scholz H, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Wu M, Basu A, Aston CE, Lyons TJ.

BJOG. 2012 Nov;119(12):1512-20. doi: 10.1111/j.1471-0528.2012.03463.x. Epub 2012 Aug 20.

29.

Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

Carlyle WC, McClain JB, Tzafriri AR, Bailey L, Zani BG, Markham PM, Stanley JR, Edelman ER.

J Control Release. 2012 Sep 28;162(3):561-7. doi: 10.1016/j.jconrel.2012.07.004. Epub 2012 Jul 16.

30.

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS.

Arch Dermatol. 2012 Sep;148(9):1031-6. doi: 10.1001/archdermatol.2012.1522.

31.

Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.

Basu A, Alaupovic P, Wu M, Jenkins AJ, Yu Y, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Dashti A, Aston CE, Lyons TJ.

J Clin Endocrinol Metab. 2012 May;97(5):1752-62. doi: 10.1210/jc.2011-3255. Epub 2012 Mar 21.

32.

Synergy of understanding dermatologic disease and epidermal biology.

Stanley JR.

J Clin Invest. 2012 Feb;122(2):436-9. doi: 10.1172/JCI62237. Epub 2012 Feb 1. Review. Erratum in: J Clin Invest. 2012 Mar 1;122(3):1131.

33.

Desmoglein as a target in skin disease and beyond.

Amagai M, Stanley JR.

J Invest Dermatol. 2012 Mar;132(3 Pt 2):776-84. doi: 10.1038/jid.2011.390. Epub 2011 Dec 22. Review.

34.

A statistical method for assessing peptide identification confidence in accurate mass and time tag proteomics.

Stanley JR, Adkins JN, Slysz GW, Monroe ME, Purvine SO, Karpievitch YV, Anderson GA, Smith RD, Dabney AR.

Anal Chem. 2011 Aug 15;83(16):6135-40. doi: 10.1021/ac2009806. Epub 2011 Jul 15.

35.

Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity.

Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR.

J Clin Invest. 2010 Nov;120(11):4111-7. doi: 10.1172/JCI44425. Epub 2010 Oct 18.

36.

Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy.

Stanley JR, Ishii K, Siegel DL, Payne AS.

Vet Dermatol. 2009 Oct;20(5-6):327-30. doi: 10.1111/j.1365-3164.2009.00836.x.

37.

Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus.

Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR.

J Immunol. 2009 Nov 1;183(9):5615-21. doi: 10.4049/jimmunol.0901691.

38.

Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence.

Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K.

J Invest Dermatol. 2009 Sep;129(9):2156-66. doi: 10.1038/jid.2009.61. Epub 2009 Apr 2.

39.

Biological and biomechanical assessment of a long-term bioresorbable silk-derived surgical mesh in an abdominal body wall defect model.

Horan RL, Bramono DS, Stanley JR, Simmons Q, Chen J, Boepple HE, Altman GH.

Hernia. 2009 Apr;13(2):189-99. doi: 10.1007/s10029-008-0459-9. Epub 2009 Feb 6.

PMID:
19198755
40.

Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women.

Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JC, Stanley JR, Dashti A, May K, Lu K, Aston CE, Wang JJ, Zhang SX, Ma JX, Lyons TJ.

Diabetologia. 2009 Jan;52(1):160-8. doi: 10.1007/s00125-008-1182-x. Epub 2008 Nov 5.

PMID:
18985316
41.

Autoimmune Bullous Diseases: Historical Perspectives.

Stanley JR, Amagai M.

J Invest Dermatol. 2008 Oct;128 Suppl 3:E16-8. doi: 10.1038/skinbio.2008.2. No abstract available.

PMID:
26875735
42.

Autoimmune bullous diseases: historical perspectives.

Stanley JR, Amagai M.

J Invest Dermatol. 2008 Oct 6;128(E3):E16-8. doi: 10.1038/skinbio.2008.2. No abstract available.

43.

Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.

Ishii K, Lin C, Siegel DL, Stanley JR.

J Invest Dermatol. 2008 Apr;128(4):939-48. Epub 2007 Nov 15.

44.

Targeting pemphigus autoantibodies through their heavy-chain variable region genes.

Payne AS, Siegel DL, Stanley JR.

J Invest Dermatol. 2007 Jul;127(7):1681-91. Epub 2007 Mar 29.

45.

Milestones in Investigative Dermatology: The Desmosome.

Kowalczyk AP, Rubenstein DS, Garrod DR, Green KJ, Stanley JR.

J Invest Dermatol. 2007 Jan;127 Suppl 3:E1. doi: 10.1038/sj.skinbio.6250007. No abstract available.

PMID:
26879533
46.

Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.

Stanley JR, Amagai M.

N Engl J Med. 2006 Oct 26;355(17):1800-10. Review. No abstract available.

PMID:
17065642
47.

Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphylococcal scalded skin syndrome.

Anzai H, Stanley JR, Amagai M.

J Invest Dermatol. 2006 Sep;126(9):2139-41. Epub 2006 May 11. No abstract available.

48.

Intraepidermal neutrophilic IgA/IgG antidesmocollin 1 pemphigus.

Heng A, Nwaneshiudu A, Hashimoto T, Amagai M, Stanley JR.

Br J Dermatol. 2006 May;154(5):1018-20. No abstract available.

PMID:
16634923
49.

Albert M. Kligman: 90 years old on March 17, 2006.

Stanley JR.

J Invest Dermatol. 2006 Apr;126(4):697-8. No abstract available.

50.

Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).

Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A.

Biol Chem. 2005 Nov;386(11):1173-84.

PMID:
16307483

Supplemental Content

Loading ...
Support Center